Skip to main content
Ruchir Shah, MD, Neurology, Chattanooga, TN

RuchirShahMD

Neurology Chattanooga, TN

Vascular Neurology

Physician

Dr. Shah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Shah's full profile

Already have an account?

  • Office

    979 E 3rd St
    Ste C830
    Chattanooga, TN 37403
    Phone+1 423-778-9001
    Fax+1 423-778-4692

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Vascular Neurology, 2014 - 2015
  • Cooper Medical School of Rowan University/Cooper University Hospital
    Cooper Medical School of Rowan University/Cooper University HospitalResidency, Neurology, 2012 - 2015
  • Grand Rapids Medical Education and Research Center/ Michigan State University (St Mary's)
    Grand Rapids Medical Education and Research Center/ Michigan State University (St Mary's)Internship, Transitional Year, 2011 - 2012
  • M.P. Shah Medical College
    M.P. Shah Medical CollegeClass of 2010

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2019 - 2026
  • IL State Medical License
    IL State Medical License 2019 - 2026
  • MS State Medical License
    MS State Medical License 2024 - 2025
  • WI State Medical License
    WI State Medical License 2023 - 2025
  • TN State Medical License
    TN State Medical License 2016 - 2025
  • OR State Medical License
    OR State Medical License 2024 - 2025
  • NY State Medical License
    NY State Medical License 2023 - 2025
  • American Board of Psychiatry and Neurology Neurology
  • American Board of Psychiatry and Neurology Vascular Neurology
  • Join now to see all

Press Mentions

  • Acticor Biotech Announces the Enrollment of the First US Patient in Its Phase 2/3 Study ACTISAVE for the Treatment of Stroke
    Acticor Biotech Announces the Enrollment of the First US Patient in Its Phase 2/3 Study ACTISAVE for the Treatment of StrokeSeptember 26th, 2022